About this trial

Cell therapy is an innovative treatment with significant efficacy in hematologic and certain autoimmune diseases. Although it offers potential benefits for autoimmune hemolytic anemia (AIHA), it may result in cognitive and other potential impairments, which can adversely affect patients' cognition and behavior.

Brain function and psychological assessment are essential for the early detection of potential impairments, allowing timely interventions to prevent complications and ensure patient safety. This study aims to comprehensively evaluate the physical and psychological impacts of cell therapy on AIHA patients to develop safer and more effective treatment strategies that enhance their quality of life.

Eligibility criteria

Qualifiers

Diagnosis of AIHA

Subjects will receive cell therapy such as CAR T-cell therapy

Male or female, aged 18-65 years

Willing and able to comply with the requirements for this study and written informed consent

Disqualifiers

History of psychiatric illness

History of severe brain disease

Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study

Trial design

Treatments tested in this trial

  • Brain function and psychological assessment

Treatment groups

20 Participants
are divided into 1 treatment group

Locations

1
Regenerative Medicine Center TianjinTianjin Municipality, China

Sponsors and collaborators

Institute of Hematology & Blood Diseases Hospital, China

Lead sponsor

Tianjin University

Collaborator